ANAPTYSBIO INC's ticker is ANAB and the CUSIP is 032724106. A total of 139 filers reported holding ANAPTYSBIO INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.3%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,454,526 | -0.2% | 80,987 | +13.1% | 0.00% | – |
| Q2 2023 | $1,456,712 | -32.1% | 71,618 | -27.4% | 0.00% | – |
| Q1 2023 | $2,146,190 | -27.8% | 98,630 | +2.8% | 0.00% | – |
| Q4 2022 | $2,972,436 | +8.3% | 95,916 | -10.8% | 0.00% | – |
| Q3 2022 | $2,744,000 | -7.8% | 107,568 | -26.7% | 0.00% | – |
| Q2 2022 | $2,976,000 | +14.6% | 146,655 | +39.7% | 0.00% | – |
| Q1 2022 | $2,597,000 | +2.8% | 104,991 | +44.4% | 0.00% | – |
| Q4 2021 | $2,527,000 | +29.5% | 72,727 | +1.1% | 0.00% | – |
| Q3 2021 | $1,951,000 | -53.4% | 71,946 | -55.5% | 0.00% | -100.0% |
| Q2 2021 | $4,191,000 | +21.9% | 161,675 | +1.3% | 0.00% | 0.0% |
| Q1 2021 | $3,438,000 | +642.5% | 159,539 | +640.6% | 0.00% | – |
| Q4 2020 | $463,000 | +324.8% | 21,543 | +189.2% | 0.00% | – |
| Q3 2020 | $109,000 | -74.9% | 7,450 | -61.6% | 0.00% | – |
| Q2 2020 | $434,000 | -93.9% | 19,396 | -96.2% | 0.00% | -100.0% |
| Q1 2020 | $7,123,000 | -58.2% | 504,094 | -51.9% | 0.00% | -50.0% |
| Q4 2019 | $17,034,000 | +137.5% | 1,048,265 | +411.5% | 0.00% | +100.0% |
| Q3 2019 | $7,171,000 | +970.3% | 204,959 | +1627.7% | 0.00% | – |
| Q2 2019 | $670,000 | -17.2% | 11,863 | +7.1% | 0.00% | – |
| Q1 2019 | $809,000 | -91.8% | 11,079 | -92.9% | 0.00% | -100.0% |
| Q4 2018 | $9,921,000 | +193.6% | 155,532 | +359.3% | 0.00% | +200.0% |
| Q3 2018 | $3,379,000 | +15.8% | 33,863 | -17.6% | 0.00% | 0.0% |
| Q2 2018 | $2,917,000 | -25.4% | 41,072 | +9.4% | 0.00% | 0.0% |
| Q1 2018 | $3,908,000 | -88.0% | 37,549 | -88.4% | 0.00% | -88.9% |
| Q4 2017 | $32,573,000 | +5865.8% | 323,394 | +1971.4% | 0.01% | – |
| Q3 2017 | $546,000 | +351.2% | 15,612 | +208.3% | 0.00% | – |
| Q2 2017 | $121,000 | -80.5% | 5,064 | -77.3% | 0.00% | – |
| Q1 2017 | $620,000 | – | 22,320 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| FRAZIER MANAGEMENT LLC | 3,688,448 | $102,354,000 | 54.68% |
| Novo Holdings A/S | 3,033,504 | $84,180,000 | 8.96% |
| BVF INC/IL | 1,738,600 | $48,246,000 | 8.21% |
| Cormorant Asset Management, LP | 895,626 | $24,854,000 | 3.61% |
| Perceptive Advisors | 881,957 | $24,474,000 | 1.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 100,500 | $2,789,000 | 1.07% |
| ACUTA CAPITAL PARTNERS, LLC | 165,690 | $4,138,000 | 0.98% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 845,746 | $23,469,000 | 0.90% |
| Iguana Healthcare Management, LLC | 50,000 | $1,388,000 | 0.69% |
| Boxer Capital, LLC | 50,000 | $1,388,000 | 0.30% |